spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Ambulatory Surgical Center Market Rising Amid Surge in Outpatient Procedures and Cost-Effective Care Delivery, 2025-2032

The Ambulatory Surgical Center Market is rapidly evolving with a shift toward outpatient surgical procedures due to improvements in surgical technologies and patient preference for cost-effective, accessible care. Increasing demand for minimally invasive surgeries and enhanced recovery protocols continues to propel ASC adoption globally.
The Global Ambulatory Surgical Center Market size is estimated to be valued at USD 52.4 billion in 2025 and is expected to reach USD 85.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.

● In 2024, the average pricing for outpatient surgeries at ambulatory surgical centers was approximately 40-60% lower than inpatient hospital costs, driving wider market acceptance.
● Supply-side indicators highlight a steady increase in ASC facility openings, with the U.S. reporting a 12% YoY growth in new surgical center establishments in 2023 alone.
● Demand-side data shows a 9% rise in outpatient orthopedic and ophthalmology procedures performed in ASCs between 2023-2024, affirming sector-specific growth momentum.
● Import-export flows of advanced surgical tools and diagnostic equipment for ASCs surged by 8.5% in 2024, correlating with expanding surgical capacity globally.
● Micro-level analysis reveals platforms offering bundled payment solutions have improved ASC case volumes by 15% in Q4 2024, reflecting innovative business models driving market revenue.

Hot this week

Daewoong Pharmaceutical Holds Talks with Saudi Officials on Bioindustry Cooperation

Daewoong Pharmaceutical said on October 17 that it met...

Novo Nordisk chair and independent directors to exit in strategy dispute

The chair of Wegovy maker Novo Nordisk and six...

Hologic to go private in up to $18.3 billion deal backed by Blackstone, TPG

Medical diagnostics firm Hologic has agreed to be acquired...

China’s Innovent signs $11.4 billion cancer therapy deal with Japan’s Takeda

-China’s Innovent Biologics said on Wednesday it had signed...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img